Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 2/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | LAP3 | P28838 | 3/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7609383 | 0.88 | MMP13 (0.48) | ACP3 | |
| SCHEMBL5051165 | 0.82 | GRM3 (0.56) | FOLH1 | |
| SCHEMBL5052931 | 0.82 | FOLH1 (0.43) | FOLH1LAP3ERAP2ERAP1ANPEP | |
| SCHEMBL5058107 | 0.82 | CYP1A2 (0.61) | FOLH1LAP3ERAP2ERAP1ANPEP | |
| SCHEMBL7352579 | 0.81 | CYP1A2 (0.65) | HRH4CTNNB1FOLH1TDP1 | |
| SCHEMBL6677809 | 0.80 | CTNNB1 (0.63) | ACP3HRH4CTNNB1TDP1 | |
| SCHEMBL5058021 | 0.79 | SMN1; SMN2 (0.55) | — | |
| SCHEMBL5060011 | 0.79 | GRM3 (0.54) | ACP3FOLH1 | |
| SCHEMBL7606727 | 0.78 | ACP3 (0.47) | ACP3 | |
| SCHEMBL7606837 | 0.78 | FOLH1 (0.53) | FOLH1LAP3ERAP2ERAP1ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | SLUSHER BARBARA S (US) | 2002-10-17 | — | — | US | claimed |
| US-6046180-A | NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 2000-04-04 | — | — | US | claimed |
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | SLUSHER BARBARA S (US) | 2002-10-17 | — | — | US | disclosed |
| US-6372726-B1 | ADMINISTERING CARBOXYALKYL PHOSPHONATE, PHOSPHORAMIDATE, OR PHOSPHINE OXIDE DERIVATIVE AS ANTITUMOR AGENT TO TREAT CANCER OF PROSTATE GLAND | GUILFORD PHARMACEUTICALS INC. | 2002-04-16 | — | — | US | disclosed |
| US-6046180-A | NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-6011021-A | GLUTAMATE-DERIVED HYDROXYPHOSPHINYL DERIVATIVE. | GUILFORD PHARMACEUTICALS INC. (US) | 2000-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | NAALAD2, DNPEP, ACP3 | ACP3 3/4885HRH4 1298/4885CTNNB1 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.